ANGPTL3 Deficiency and Risk of Hepatic Steatosis.
Laura D'ErasmoMichele Di MartinoThomas NeufeldTyler J FraumChul Joo KangKendall H BurksAlessia Di CostanzoIlenia MinicocciSimone BiniMarianna MaranghiGiovanni PignaGiancarlo LabbadiaJie ZhengDavide FierroAnna MontaliFabrizio CeciCarlo CatalanoNicholas O DavidsonGiuseppe LucisanoAntonio NicolucciMarcello ArcaNathan O StitzielPublished in: Circulation (2023)
, as well as genetically determined reduction of plasma ANGPTL3 levels, is not associated with hepatic steatosis. Therapeutic approaches to inhibit ANGPTL3 production in hepatocytes are not necessarily expected to result in the increased risk for hepatic steatosis that was observed with vupanorsen.
Keyphrases